Molecular subtyping of Alzheimer’s disease using RNA sequencing data reveals novel mechanisms and targets

Abstract excerpt

We further demonstrate that variations between existing AD mouse models recapitulate a certain degree of subtype heterogeneity, which may partially explain why a vast majority of drugs that succeeded in specific mouse models do not align with generalized human trials across all AD subtypes. Therefore, subtyping patients with AD is a critical step toward precision medicine for this devastating disease.

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Alzheimer's disease research and treatments
• Share to Bioinformatics and Genomic Networks
• Share to Machine Learning in Bioinformatics